Abstract
A new phenylboric acid derivative entrapped lipiodol (PBAD-lipiodol) was developed as a boron carrier for the boron neutron capture therapy (BNCT) of hepatoma in Taiwan. The biodistribution of both PBAD-lipiodol and BPA-fructose was assayed in GP7TB hepatoma-bearing rat model. The highest uptake of PBAD-lipiodol was found at 2h post injection. The application of BNCT for the hepatoma treatment in tumor-bearing rats is suggested to be 2-4h post PBAD-lipiodol injection.
Copyright 2009 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Boron Neutron Capture Therapy / methods*
-
Boronic Acids / chemical synthesis
-
Boronic Acids / pharmacokinetics*
-
Boronic Acids / pharmacology
-
Fluorine Radioisotopes / pharmacokinetics*
-
Fluorine Radioisotopes / pharmacology
-
Iodized Oil / chemical synthesis
-
Iodized Oil / pharmacokinetics*
-
Iodized Oil / pharmacology
-
Liver Neoplasms, Experimental / metabolism*
-
Liver Neoplasms, Experimental / radiotherapy
-
Magnetic Resonance Imaging
-
Male
-
Phenylalanine / analogs & derivatives*
-
Phenylalanine / chemical synthesis
-
Phenylalanine / pharmacokinetics
-
Phenylalanine / physiology
-
Rats
-
Rats, Inbred F344
-
Tissue Distribution
Substances
-
Boronic Acids
-
Fluorine Radioisotopes
-
Phenylalanine
-
Iodized Oil